Revista Brasileira de Cirurgia Cardiovascular
versão impressa ISSN 0102-7638
VRANDECIC, Mário O et al. Heterologous mitral valve transplant: New surgical technique: initial clinical trial. Rev Bras Cir Cardiovasc [online]. 1993, vol.8, n.2, pp. 83-90. ISSN 0102-7638. http://dx.doi.org/10.1590/S0102-76381993000200002.
Mitral valve replacement has been performed for the last 30 years using an aortic designed valve, to fulfil specific requirements of the left ventricle. The clinical results obtained by such devices have been generally favorable, although specific restrictions are obvious because of their design. The knowledge and experience acquired by Biocor Laboratories in the last two decades, in production of biological heart valve substitutes, contributed positively to the research, development and manufacture of the heterologous mitral valve substitute. This stentless heterologous mitral valve was implanted in 38 patients, without hospital mortality. Their mean age was 29 years. Female gender predominated (69%). The most common mitral dysfunction was the double mitral valve lesion (53%). Eighteen (47%) patients were in functional class III and 20 (53%) in class IV of the NYHA. There was one valve related complication (our first patient), due to disproportion of patients, large annulus and the incorrectly size chosen. This complication led us to the strict adherence of our protocol, which is based upon animal experimentation. The satisfactory operatory and clinical results, throughout this 12 months of follow-up, confirm that the stentless heterologous mitral valve is the natural mitral substitute, when considering mitral valve replacement. This first natural mitral valve substitute, tanned with a non-aldehyde tissue treatment, proved to avoid calcification and to produce no foreign reaction, hence it may be the best choice in order to obtain better quality of life and the desired valve durability. Using both, the natural design mitral valve and the non-aldehyde treatment, the last 6 patients of this series received this devicxe and is certainly hoped that, due to the more natural model and the non-calcificant and inhert tissue, patients own cells will be responsible to greatly delay tissue degeneration, providing longterm durability.
Palavras-chave : heart valves, mitral [surgery]; heart valves [surgery].